NeoGenomics Inc. (NG9)
XMUN 
Summary
NG9 Chart
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Neo Performance Materials Q2 Earnings Call Highlights
Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NeoGenomics Inc. (NG9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NeoGenomics Inc. ever had a stock split?
NeoGenomics Inc. Profile
| Professional Services Industry | Industrials Sector | Anthony Zook CEO | XMUN Exchange | US64049M2098 ISIN |
| US Country | 2,500 Employees | 17 Dec 2020 Last Dividend | 16 Apr 2003 Last Split | 2 Nov 1999 IPO Date |
Overview
NeoGenomics, Inc. is a specialized laboratory network that focuses on cancer diagnostics and operates within the United States and the United Kingdom. Since its inception in 2001 and based in Fort Myers, Florida, the company has grown to provide a comprehensive range of testing services through its Clinical Services and Advanced Diagnostics segments. These services cater to an array of clients including hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. With a strong emphasis on supporting the diagnosis, treatment, and monitoring of cancer, NeoGenomics stands out for its dedication to advancing oncology diagnostics.
Products and Services
NeoGenomics, Inc. offers a diverse portfolio of diagnostic services, further detailed below:
- Cytogenetics Testing Services: This service examines both normal and abnormal chromosomes to understand their link to diseases. It's pivotal for revealing genetic conditions related to chromosome abnormalities.
- Fluorescence In-Situ Hybridization (FISH) Testing Services: Specializing in detecting and pinpointing the presence or absence of specific DNA sequences and genes on chromosomes, FISH plays a crucial role in genetic disease diagnosis and management.
- Flow Cytometry Testing Services: By measuring the physical and chemical characteristics of cell populations, this service provides invaluable data for research and clinical purposes, particularly in hematology.
- Immunohistochemistry and Digital Imaging Testing Services: These services focus on localizing cellular proteins in tissue sections. Moreover, they enable clients to visualize scanned slides and perform quantitative analyses, enhancing diagnostic precision.
- Molecular Testing Services: This service focuses on the analysis of DNA and/or RNA, along with the structure and function of genes at the molecular level, which is essential for the diagnosis of genetic disorders, infectious diseases, and cancers.
- Morphologic Analysis: Conducting an examination of cells under a microscope allows pathologists to diagnose various conditions accurately based on the appearance and structure of cells.
- Pharmaceutical Services: Supporting pharmaceutical clients’ oncology programs, these services range from the discovery phase through to commercialization, thus facilitating the development of new cancer treatments.
